Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Introduction: Acute antibody-mediated rejection (ABMR) is one of the main causes of loss of graft function. When the diagnosis is made by renal biopsy, treatment is granted. Treatment might cosist of plasma exchange sessions, human immunoglobulin infussion, methylprednisolone boluses and Rituximab. However, after receiving treatment, 40-64% of patients persist with ABMR; therefore, it is important to identify risk factors for lack of treatment response of ABMR to try to influence in them.
Material and Methods: Retrospective cohort study. Medical records were reviewed in an Institutional platform. Bivariate (Fisher's exact) and multivariate (Cox's regression) statistical analyses of different factors (treatment variables and independent patients’ variables) were performed to obtain an odds ratio and identify risk factors.
Results: A total of 51 patients with a diagnosis of ABMR were included, who received treatment with plasma exchange 3-5 sessions, infusion of human immunoglobulin 0.5-1 mg/Kg, boluses of methylprednisolone 6-12 mg/Kg and infusion of Rituximab 500 mg. Patient-specific variables (sex, age, living or cadaveric transplant, time from transplant to rejection, type of induction drug, degree of inflammation of the microvasculature, interstitial fibrosis, amount of MFI, the time from the date of diagnosis to the start of treatment) and factors associated with treatment (number of TPE sessions [3 vs 5 sessions], dose of human immunoglobulin [0.5 mg/kg vs 1 mg/kg], methylprednisolone [6 mg/kg vs 12 mg/kg] and whether or not Rituximab was infused) were taken into account. In the patient's variables, in the bivariate analysis, a tendency to treatment failure was observed in the G+PTC score (OR 2.0; CI 0.65-6.19, p=0.25), IFTA >25% (OR 2.27; CI 0.43-13.13, p=0.09), type of drug induction (Thymoglobulin vs Basiliximab. OR 2.0; CI 0.63-6.35, p=0.26) and time of more than one year from transplant to rejection (OR 2.89; CI 0.53-15.58, p=0.27). In the case of sex, a greater frequency of response was observed in female sex compared to men sex (OR 2.44; CI 0.78-7.66, p=0.12). The multivariate analysis was performed with the variables that had a statistical trend and only statistical significance was observed in the female sex (HR 0.14; CI 0.03-0.47, p<0.05) and the time from transplant to rejection (HR 0.93; CI 0.89-0.96, p<0.05). In the case of treatment, a greater frequency of response was observed in case of having received 3 sessions versus 5 sessions (p<0.007). In the rest of the variables analyzed there were no significant differences.
Conclusion: Male sex and time of diagnosis of ABMR after one year of transplant are risk factors for failure of ABMR treatment, and receiving 3 sessions has a higher frequency of response compared to 5 sessions. Based on these findings, measures such as optimal immunosuppression, closer monitoring in case these factors are present can be implemented. As for treatment, only three plasma exchange sessions are necessary to provide adequate treatment for ABMR. In addition to this, reduce costs, secondary risk associated to plasma exchange and immunosuppression to the patient.
